Advertisement

Topics

FDA Approves RITUXAN HYCELA (Rituximab and Hyaluronidase Human) for Subcutaneous Injection in Certain Blood Cancers

14:19 EDT 22 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
– Treatment can be administered in five to seven minutes, compared to 1.5 hours or more for intravenous Rituxan – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food an...

Other Sources for this Article

Genentech
Media Contact:
Holli Kolkey, 650-467-6800
or
Advocacy Contact:
Angela Wilson, 202-423-2739
or
Investor Contacts:
Neera Dahiya Ravindran, M.D., 650-491-5281
Karl Mahler, 011 41 61 687 8503

NEXT ARTICLE

More From BioPortfolio on "FDA Approves RITUXAN HYCELA (Rituximab and Hyaluronidase Human) for Subcutaneous Injection in Certain Blood Cancers"

Advertisement
Quick Search
Advertisement
Advertisement